prikaz prve stranice dokumenta Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)
  Download
PDF 391.14 KB
Scientific paper - Review paper
Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)
Molecular Medicine Reports, 24 (2021), 2; 611. https://doi.org/10.3892/mmr.2021.12250
Nadalin, Sergej; Jakovac, Hrvoje; Peitl, Vjekoslav; Karlović, Dalibor; Buretić-Tomljanović, Alena

Linked objects
COVID-19 | Virtual collection

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Nadalin, S., Jakovac, H., Peitl, V., Karlović, D. & Buretić Tomljanović, A. (2021). Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review). Molecular Medicine Reports, 24. (2). doi: 10.3892/mmr.2021.12250

Nadalin, Sergej, et al. "Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)." Molecular Medicine Reports, vol. 24, no. 2, 2021. https://doi.org/10.3892/mmr.2021.12250

Nadalin, Sergej, Hrvoje Jakovac, Vjekoslav Peitl, Dalibor Karlović and Alena Buretić Tomljanović. "Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)." Molecular Medicine Reports 24, no. 2 (2021). https://doi.org/10.3892/mmr.2021.12250

Nadalin, S., et al. (2021) 'Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)', Molecular Medicine Reports, 24(2). doi: 10.3892/mmr.2021.12250

Nadalin S, Jakovac H, Peitl V, Karlović D, Buretić Tomljanović A. Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review). Molecular Medicine Reports [Internet]. 2021 June 28 [cited 2024 November 08];24(2). doi: 10.3892/mmr.2021.12250

S. Nadalin, H. Jakovac, V. Peitl, D. Karlović and A. Buretić Tomljanović, "Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)", Molecular Medicine Reports, vol. 24, no. 2, June 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:410278. [Accessed: 08 November 2024]

Metadata
Title (english)Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)
AuthorSergej Nadalin
AuthorHrvoje Jakovac
AuthorVjekoslav Peitl
AuthorDalibor Karlović
AuthorAlena Buretić-Tomljanović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Physiology, Immunology and Pathophxsiology)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Human Genetics, Genomics and Proteomics
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Immunology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Psychiatry
Abstract (english)
Genetic and nongenetic factors associated with an increased inflammatory response may mediate a link between severe coronavirus disease 2019 (COVID‑19) and serious mental illness (SMI). However, systematic assessment of inflammatory response‑related factors associated with SMI that could influence COVID‑19 outcomes is lacking. In the present review, dietary patterns, smoking and the use of psychotropic medications are discussed as potential extrinsic risk factors and angiotensin‑converting enzyme (ACE) insertion/deletion (I/D) gene polymorphisms are considered as potential intrinsic risk factors. A genetics‑based prediction model for SMI using ACE‑I/D genotyping is also proposed for use in patients experiencing severe COVID‑19. Furthermore, the literature suggests that ACE inhibitors may have protective effects against SMI or severe COVID‑19, which is often linked to hypertension and other cardiovascular comorbidities. For this reason, we hypothesize that using these medications to treat patients with severe COVID‑19 might yield improved outcomes, including in the context of SMI associated with COVID‑19.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleMolecular Medicine Reports
Numberingvol. 24, no. 2, 611
p-ISSN1791-2997
e-ISSN1791-3004
DOIhttps://doi.org/10.3892/mmr.2021.12250
URN:NBNurn:nbn:hr:184:410278
Online first2021-06-28
Document URLhttp://www.spandidos-publications.com/10.3892/mmr.2021.12250
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2021-09-07 09:23:33